influenza
viru
capabl
caus
seriou
diseas
result
hospit
death
especi
elderli
individu
year
age
influenza
pandem
kill
nearli
million
peopl
worldwid
elderli
highest
abbrevi
recombin
onchocerca
volvulu
activationassoci
secret
tiv
trival
inactiv
influenza
vaccin
hau
hemagglutin
unit
mortal
rate
strong
primari
immun
respons
import
protect
influenza
virus
sinc
chang
antigen
epitop
virus
occur
rapidli
immun
respons
alter
diminish
age
leav
elderli
suscept
infecti
diseas
cdc
estim
season
flu
season
fluassoci
death
rang
peopl
cdc
death
among
elderli
immun
best
way
prevent
season
epidem
pandem
influenza
two
differ
vaccin
present
use
unit
state
kill
vaccin
trival
inactiv
influenza
vaccin
tiv
util
sinc
live
attenu
vaccin
approv
fda
peopl
age
vaccin
effect
young
adult
diminish
efficaci
tiv
consist
found
elderli
recipi
influenza
vaccin
approv
use
individu
weaken
immun
system
elderli
high
dose
tiv
vaccin
report
increas
antibodi
respons
reduc
develop
influenza
elderli
compar
tradit
dose
tiv
howev
neither
dose
total
prevent
diseas
addit
increas
antigen
dose
use
adjuv
proven
approach
enhanc
immunogen
protect
efficaci
vaccin
adjuv
also
shown
enhanc
crossreact
respons
howev
present
adjuv
commerci
avail
use
human
aluminum
salt
alum
first
adjuv
approv
unit
state
gener
use
vaccin
mani
influenza
vaccin
commerci
avail
unit
state
europ
alumadsorb
howev
alum
remov
influenza
vaccin
formul
earli
larg
clinic
data
show
margin
enhanc
antibodi
respons
induc
increas
advers
effect
protein
adjuv
potenti
mice
discov
recent
helminth
parasit
onchocerca
volvulu
volvulu
activationassoci
secret
member
famili
protein
found
freeliv
parasit
nematod
recombin
predict
molecular
weight
kd
adjuvant
studi
use
ovalbumin
sarscov
peptid
antigen
sever
commerci
avail
vaccin
function
adjuv
enhanc
also
strong
immun
respons
latter
critic
stimul
antivir
immun
respons
previous
report
coadministr
tiv
use
aqueou
formul
significantli
improv
influenzaspecif
antibodi
respons
protect
lethal
infect
young
mice
current
studi
found
similarli
enhanc
influenzaspecif
respons
tiv
age
mice
twomonthand
mice
obtain
nia
harlan
spragu
dawley
indianapoli
mice
maintain
aaalacapprov
barrier
facil
drexel
univers
philadelphia
pa
mice
allow
acclim
least
one
week
anim
facil
prior
use
experi
involv
mice
conduct
approv
institut
anim
care
use
committe
iacuc
drexel
univers
mice
exhibit
enlarg
spleen
tumor
elimin
studi
influenza
vaccin
use
studi
commerci
avail
tiv
contain
g
influenza
viru
hemagglutinin
ha
follow
virus
nymc
nymc
formula
fluarix
glaxosmithklin
ml
volum
mice
immun
intramuscularli
im
g
tiv
tiv
mix
purifi
deriv
recombin
escherichia
coli
gmous
salin
adjuv
comparison
control
mice
immun
tiv
mix
imject
alum
thermo
scientif
mgmous
ratio
alum
antigen
volum
mice
bled
tail
weekli
week
postimmun
plasma
util
assay
influenza
apuerto
viru
strain
propag
specif
pathogenfre
fertil
chicken
egg
previous
describ
group
mice
challeng
intranas
day
post
primari
immun
mice
anesthet
intraperiton
ketaminexylazin
mg
ketamin
mg
xylazin
infect
l
steril
salin
contain
haumous
protect
efficaci
immun
measur
surviv
day
mice
lost
initi
bodi
weight
sacrif
accord
institut
guidelin
influenzaspecif
antibodi
respons
measur
elisa
previous
describ
briefli
well
elisa
plate
coat
tiv
gml
ha
uvinactiv
strain
influenza
viru
hauml
bound
antibodi
plasma
detect
goat
antimous
igg
antibodi
molecular
probesinvitrogen
titer
antibodi
defin
reciproc
highest
dilut
plasma
give
optic
densiti
od
greater
time
mous
sampl
limit
detect
lod
igg
titer
indic
experi
respect
figur
unpair
twotail
student
ttest
use
determin
differ
immun
respons
group
mice
signific
surviv
rate
analyz
logrank
mantelcox
test
antibodi
titer
express
mean
sem
sinc
antibodi
plasma
quantit
use
serial
dilut
elisa
compar
differ
level
antibodi
differ
group
log
convert
antibodi
titer
result
consid
statist
signific
p
valu
less
examin
enhanc
specif
igg
respons
tiv
age
mice
age
mice
immun
im
tiv
without
three
week
immun
influenzaspecif
igg
antibodi
plasma
determin
elisa
shown
fig
immun
tiv
alon
specif
igg
observ
young
adult
mice
previous
report
level
antibodi
age
mice
lod
howev
immun
tiv
igg
level
significantli
increas
young
adult
age
mice
tiv
vs
tiv
young
p
age
p
igg
titer
increas
time
age
mice
time
young
adult
mice
importantli
level
igg
age
mice
immun
tiv
compar
young
adult
mice
immun
tiv
alon
p
data
demonstr
significantli
enhanc
specif
antibodi
respons
tiv
young
adult
age
mice
compar
adjuv
effect
convent
adjuv
alum
immun
age
mice
im
g
tiv
alon
g
mg
alum
fig
mice
immun
higher
dose
tiv
alon
gmous
includ
investig
provid
antigen
spare
three
week
vaccin
influenzaspecif
igg
plasma
determin
elisa
shown
fig
addit
either
alum
significantli
enhanc
influenzaspecif
igg
respons
compar
tiv
alon
tiv
vs
tiv
p
tiv
vs
tiv
alum
p
howev
titer
igg
significantli
higher
use
compar
alum
p
interestingli
signific
differ
igg
level
observ
low
high
dose
tiv
given
alon
p
indic
antibodi
respons
tiv
improv
age
mice
simpli
increas
dose
vaccin
enhanc
influenzaspecif
antibodi
respons
age
mice
antibodi
respons
induc
influenza
vaccin
play
import
role
protect
influenza
infect
therefor
investig
abil
enhanc
antibodi
respons
age
mice
report
unlik
balbc
mice
mice
gene
express
differ
antibodi
crossreact
therefor
determin
influenzaspecif
titer
three
week
im
immun
tiv
tiv
titer
plasma
determin
elisa
shown
fig
tiv
alon
induc
respons
significantli
enhanc
level
compar
tiv
alon
p
tiv
alon
howev
induc
detect
coadministr
induc
high
level
compar
tiv
alon
p
also
compar
level
result
demonstr
primari
immun
age
mice
tiv
induc
increas
respons
importantli
elicit
signific
influenzaspecif
respons
occur
tiv
alon
induct
crossreact
antibodi
particularli
import
influenza
vaccin
sinc
frequent
chang
ha
requir
yearli
immun
year
lead
loss
vaccin
efficaci
due
mismatch
vaccin
compon
circul
virus
viru
mouseadapt
influenza
viru
fig
enhanc
influenzaspecif
antibodi
respons
age
mice
twentytwo
month
old
mice
immun
im
tiv
alon
gmous
admix
tiv
asp
three
week
immun
influenzaspecif
level
examin
plasma
use
elisa
pool
experiment
data
repres
mice
group
two
experi
p
isol
viru
differ
substanti
recent
isol
nymc
strain
compon
tiv
report
enhanc
crossreact
igg
respons
young
adult
mice
provid
protect
infect
induc
antigen
differ
strain
test
could
enhanc
crossreact
antibodi
respons
age
mice
well
mice
immun
im
tiv
tiv
crossreact
respons
week
post
primari
immun
determin
elisa
plate
coat
inactiv
viru
crossreact
antibodi
detect
week
either
immun
data
shown
week
crossreact
antibodi
level
detect
mice
immun
tiv
crossreact
antibodi
detect
tiv
alon
group
week
margin
level
detect
week
fig
data
demonstr
tiv
induc
crossreact
antibodi
respons
howev
lower
level
previous
observ
young
adult
mice
abil
enhanc
efficaci
tiv
influenza
viru
challeng
examin
age
mice
age
mice
immun
im
tiv
alon
alum
challeng
three
week
later
influenza
viru
shown
fig
tiv
alon
afford
protect
viru
infect
surviv
vs
surviv
control
tiv
group
tiv
alum
group
surviv
importantli
tiv
immun
group
tiv
alum
immun
mice
demonstr
influenza
diseas
base
loss
bodi
weight
tiv
show
weight
loss
averag
weight
loss
day
tiv
alum
group
tiv
p
result
indic
potenti
enhanc
surviv
diseas
protect
age
mice
even
antigen
distinct
viru
annual
vaccin
influenza
key
strategi
employ
combat
ill
effect
healthi
young
adult
howev
much
less
success
elderli
dysregul
immun
respons
seen
age
contribut
diminish
abil
vaccin
provid
protect
report
increas
dose
antigen
fourfold
effect
increas
diminish
respons
elderli
found
level
influenzaspecif
igg
plasma
age
mice
significantli
enhanc
administr
fold
higher
dose
tiv
fig
therefor
suggest
addit
altern
need
explor
one
potenti
strategi
improv
vaccin
efficaci
inclus
adjuv
vaccin
formul
adjuv
shown
improv
antibodi
product
enabl
antigen
dosespar
potenti
increas
crossreact
benefit
import
combat
season
influenza
pandem
influenza
effect
current
season
vaccin
depend
close
match
circul
viru
pandem
vaccin
need
quickli
produc
adjuv
approv
commerci
use
human
unit
state
adjuvant
discov
helminth
parasit
volvulu
studi
use
ovalbumin
polypeptid
sarscov
peptid
subunit
antigen
sever
commerci
avail
vaccin
demonstr
young
adult
mice
effect
adjuv
acceler
enhanc
influenzaspecif
antibodi
respons
induc
tiv
allow
antigen
spare
augment
crossreact
antibodi
respons
confer
heterolog
protect
current
studi
confirm
previou
studi
immun
inactiv
influenza
vaccin
induc
significantli
lower
level
igg
age
vs
young
mice
fig
howev
coadminist
influenzaspecif
igg
significantli
increas
age
mice
higher
immun
higher
dose
tiv
alon
importantli
compar
young
adult
mice
receiv
tiv
alon
fig
tiv
increas
antibodi
respons
fig
interestingli
bungen
et
al
demonstr
mice
immun
influenza
vaccin
plu
alum
show
enhanc
respons
suffer
sever
weight
loss
significantli
higher
viru
load
lung
receiv
vaccin
alon
sinc
alum
first
adjuv
approv
unit
state
gener
use
vaccin
although
present
current
avail
commerci
influenza
vaccin
compar
efficaci
alum
induc
influenzaspecif
igg
respons
tiv
observ
superior
alum
enhanc
influenzaspecif
igg
respons
fig
although
surviv
rate
similar
alum
fig
effect
decreas
sign
diseas
base
weight
loss
ideal
influenza
vaccin
would
abl
offer
broad
crossreact
immun
differ
strain
influenza
viru
report
attenu
inactiv
influenza
vaccin
may
induc
crossprotect
immun
antigen
distinct
viru
strain
mice
crossreact
antibodi
usual
target
ha
stem
region
sinc
conserv
part
ha
howev
antibodi
rare
seen
human
infect
vaccin
season
influenza
viru
strain
previou
studi
young
adult
mice
demonstr
could
enhanc
product
crossreact
antibodi
confer
protect
infect
caus
heterolog
strain
influenza
present
studi
found
tiv
induc
low
level
crossreact
antibodi
whole
viru
age
mice
week
primari
immun
tiv
alon
fig
find
age
mice
differ
observ
young
adult
mice
crossreact
igg
antibodi
ha
detect
plasma
secondari
although
primari
immun
tiv
interestingli
howev
primari
immun
young
adult
age
mice
fig
protect
observ
challeng
antigen
differ
strain
influenza
viru
protect
provid
tiv
may
associ
low
level
crossreact
igg
antibodi
age
mice
similar
observ
age
popul
immun
tiv
significantli
lower
level
antibodi
respons
circul
influenza
viru
show
influenza
symptom
infect
influenza
viru
demonstr
decreas
hospit
pneumonia
influenza
also
reduc
risk
death
caus
tiv
use
studi
inactiv
flu
vaccin
induc
cell
respons
still
unclear
induc
enhanc
cell
respons
import
sinc
specif
cell
respons
critic
elimin
viru
infect
evalu
effect
adjuv
prevent
infecti
diseas
focu
primari
defens
mechan
associ
agent
includ
cell
respons
cell
induc
cytokin
summari
found
significantli
enhanc
influenzaspecif
igg
respons
immun
tiv
age
mice
importantli
level
igg
age
mice
administ
tiv
compar
young
adult
mice
immun
tiv
alon
superior
alum
induc
high
level
specif
igg
tiv
immun
age
mice
tiv
tiv
alum
tiv
alon
induc
protect
immun
age
mice
antigen
differ
strain
influenza
viru
reflect
increas
surviv
decreas
weight
loss
challeng
superior
alum
prevent
diseas
indic
weight
loss
result
suggest
may
serv
potenti
adjuv
enhanc
protect
efficaci
influenza
vaccin
elderli
import
implic
decreas
morbid
mortal
influenza
popul
jj
parttim
employe
dmx
inc
